BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Director V Bryan Lawlis sold 3,750 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $88.84, for a total value of $333,150.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Shares of BioMarin Pharmaceutical Inc. (NASDAQ BMRN) opened at $90.22 on Friday. BioMarin Pharmaceutical Inc. has a 52-week low of $80.10 and a 52-week high of $100.51. The company has a quick ratio of 3.81, a current ratio of 4.91 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $15,802.40, a price-to-earnings ratio of -100.24 and a beta of 1.82.
BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Thursday, October 26th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. BioMarin Pharmaceutical had a negative return on equity of 4.60% and a negative net margin of 12.45%. The firm had revenue of $334.18 million for the quarter, compared to analyst estimates of $347.38 million. During the same period last year, the company earned $0.02 earnings per share. The firm’s revenue for the quarter was up 19.4% on a year-over-year basis. equities analysts anticipate that BioMarin Pharmaceutical Inc. will post -0.64 EPS for the current fiscal year.
Several equities analysts have recently commented on the company. Leerink Swann reiterated an “outperform” rating and set a $142.00 target price (up from $136.00) on shares of BioMarin Pharmaceutical in a research note on Thursday, October 19th. SunTrust Banks set a $115.00 target price on BioMarin Pharmaceutical and gave the company a “buy” rating in a research note on Thursday, October 19th. Piper Jaffray Companies reiterated a “buy” rating and set a $113.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, September 21st. Wedbush upgraded BioMarin Pharmaceutical from a “neutral” rating to an “outperform” rating and set a $110.00 price objective on the stock in a research note on Thursday, December 14th. Finally, BidaskClub upgraded BioMarin Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 16th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $112.32.
A number of hedge funds and other institutional investors have recently modified their holdings of BMRN. Vanguard Group Inc. increased its holdings in shares of BioMarin Pharmaceutical by 4.7% during the second quarter. Vanguard Group Inc. now owns 14,345,027 shares of the biotechnology company’s stock valued at $1,302,816,000 after purchasing an additional 642,623 shares during the period. TIAA CREF Investment Management LLC increased its holdings in shares of BioMarin Pharmaceutical by 63.7% during the second quarter. TIAA CREF Investment Management LLC now owns 2,251,011 shares of the biotechnology company’s stock valued at $204,437,000 after purchasing an additional 875,686 shares during the period. Pictet Asset Management Ltd. increased its holdings in shares of BioMarin Pharmaceutical by 17.0% during the third quarter. Pictet Asset Management Ltd. now owns 1,134,622 shares of the biotechnology company’s stock valued at $105,599,000 after purchasing an additional 164,788 shares during the period. Northern Trust Corp increased its holdings in shares of BioMarin Pharmaceutical by 2.9% during the second quarter. Northern Trust Corp now owns 1,097,571 shares of the biotechnology company’s stock valued at $99,682,000 after purchasing an additional 31,113 shares during the period. Finally, TCW Group Inc. increased its holdings in shares of BioMarin Pharmaceutical by 20.1% during the third quarter. TCW Group Inc. now owns 1,072,969 shares of the biotechnology company’s stock valued at $99,862,000 after purchasing an additional 179,879 shares during the period. 99.02% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “Insider Selling: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Director Sells 3,750 Shares of Stock” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/01/13/v-bryan-lawlis-sells-3750-shares-of-biomarin-pharmaceutical-inc-bmrn-stock.html.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.